Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 8 Jun 2023

Sowah Leonard A, Smeaton Laura, Brates Irena, Bhattacharya Debika, Linas Benjamin, Kreter Bruce, Wagner-Cardoso Sandra, Solomon Sunil, Sulkowski Mark, Robbins Gregory K

Abstract excerpt

BACKGROUND: With the advent of efficacious oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV), identification of characteristics associated with adherence is critical to treatment success. We examined correlates of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial. METHODS: ACTG A5360 enrolled HCV treatment-naive persons without decompensated cirrhosis from 5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 36694361
DOI: 10.1093/cid/ciad034
PMCID: PMC10249990

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.PMID 36694361Read ↗

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.Semantic proximity Read ↗

Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.Semantic proximity Read ↗

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Semantic proximity Read ↗

Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.Semantic proximity Read ↗

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.Semantic proximity Read ↗

Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.Semantic proximity Read ↗

Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial.Semantic proximity Read ↗

IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C.Semantic proximity Read ↗

Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response.Semantic proximity Read ↗

Development of a machine learning model to predict short duration HCV treatment responseSemantic proximity Read ↗

A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.Semantic proximity Read ↗

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.